Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Acta Cardiol ; 55(4): 247-53, 2000 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-11041123

RESUMO

The purpose of this study was to evaluate the changes in tissue-plasminogen activator (t-PA), plasminogen activator inhibitor - type 1 (PAI-1) and D-dimer (DD) antigen plasma levels in acute myocardial infarction (AMI) patients after thrombolytic therapy with two different thrombolytic agents, rt-PA or acetyl-streptokinase and to find out any correlation between the plasma t-PA, PAI-1 and DD levels with the infarct size as it is estimated from the peak of serum CPK levels. The plasma antigen levels of t-PA, PAI-1 and DD were measured by the enzyme immunoassay method (Stago), in 57 consecutive patients (M = 46, F = 11, mean age 55.6 +/- 8.8 years) and in 25 normal subjects (M = 18, F = 7, mean age 54.0 +/- 5.5 years). In 47 out of the 57 patients who were treated successfully with 100 mg of rt-PA (26 patients) or with 1.5 MU 21 of acetyl-streptokinase, as well as in 10 patients who were not treated, samples were obtained again 4 and 24 hours after the end of thrombolytic therapy or admission, respectively. During the acute phase of myocardial infarction the t-PA, PAI-1 and DD antigen plasma levels were significantly higher than in healthy people. There were no significant changes in the t-PA, PAI-1 and DD plasma levels of the patients who were not treated with a thrombolytic agent. We found a significant elevation of t-PA (p < 0.001), PAI-1 (p < 0.05) and DD (p < 0.001) after 4 hours in comparison with the baseline (at presentation, before therapy). After 24 hours the t-PA and DD plasma levels remained significantly higher (p < 0.001) while the PAI-1 plasma levels returned to the pre-therapy levels. There were no significantly different changes in the t-PA, PAI-1 and DD plasma levels of either group of patients, treated with rt-PA or acetyl-streptokinase while the t-PA and PAI-1 levels were positively correlated with infarct size as estimated from peak serum CPK levels.


Assuntos
Produtos de Degradação da Fibrina e do Fibrinogênio/análise , Fibrinólise , Infarto do Miocárdio/sangue , Infarto do Miocárdio/tratamento farmacológico , Inibidor 1 de Ativador de Plasminogênio/sangue , Ativadores de Plasminogênio/uso terapêutico , Estreptoquinase/uso terapêutico , Terapia Trombolítica , Ativador de Plasminogênio Tecidual/uso terapêutico , Ensaios Enzimáticos Clínicos , Creatina Quinase/sangue , Feminino , Humanos , Técnicas Imunoenzimáticas , Modelos Lineares , Masculino , Pessoa de Meia-Idade , Infarto do Miocárdio/diagnóstico , Ativadores de Plasminogênio/antagonistas & inibidores , Ativadores de Plasminogênio/sangue , Fatores de Tempo , Ativador de Plasminogênio Tecidual/sangue
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...